Targeted therapies directed to tumor-associated antigens are being investigated for the treatment of cancer. However, there are few suitable animal models for testing the ability to target these tumor markers. Therefore, we have exploited mice transgenic for the human coxsackie and adenovirus receptor (hCAR) to establish a new model for transient expression of human tumor-associated antigens in the pulmonary vasculature. Systemic administration of Ad in hCAR mice resulted in an increase in transgene expression in the lungs compared to wild-type mice, as determined using a luciferase reporter gene. To reduce transgene expression in the liver, the predominant organ of ectopic Ad localization and transgene expression following systemic administration, we utilized the endothelial-specific flt-1 promoter, which resulted in a further increased lung-to-liver ratio of luciferase expression. Administration of an adenoviral vector encoding the tumor-associated antigen carcinoembryonic antigen (CEA) under transcriptional control of the flt-1 promoter resulted in selective expression of this antigen in the pulmonary vasculature of hCAR mice. Feasibility of targeting to expressed CEA was subsequently demonstrated using adenoviral vectors preincubated with a bifunctional adapter molecule recognizing this tumor-associated antigen, thus demonstrating utility of this transient transgenic animal model.
Introduction
Despite recent technical advances in conventional anticancer modalities such as surgery, radiotherapy, and chemotherapy, overall mortality from neoplastic disease only slightly decreased. In this regard, the definition of the molecular basis of cancer has provided the rationale for therapeutic interventions designed to correct the responsible abnormalities. Targeted agents offer the theoretical possibility of greatly improving the therapeutic index of antitumor therapies via a reduction in ectopic localization and treatment-associated toxicities. Candidate targeted therapies have recently been translated to human clinical context and indices of efficacy have been reported. Such targeted therapies have included radioimmunotherapy and therapy with immunotoxins, as well as gene therapy and virotherapy. [1] [2] [3] [4] The functional basis of a subset of targeted cancer therapies involves directing the anti-cancer payload selectively to tumor sites by exploiting cell surface markers expressed preferentially on the target tumor cells. Several of these cell surface markers -or tumorassociated antigens (TAAs) -have been identified, such as carcinoembryonic antigen (CEA) for colon cancer, 5 p185 erbB2 for breast cancer, 6 and epidermal growth factor receptor (EGF-R) for a range of epithelial neoplasms. 7 Few transgenic murine models expressing these antigens have been developed in order to preclinically evaluate targeted agents for the capacity to bind selectively the tumor antigen in an in vivo context. 8, 9 However, there are significant limitations associated with these currently available models. The most noteworthy of these is that only a restricted repertoire of candidate tumor antigens has been employed in transgenic murine models. This reflects the technical difficulties involved in transgenic mouse development, which is based, in part, on conditional lethalities associated with selected tumor antigens. Thus, a murine model that would provide transient expression of tumor antigens of interest would be highly useful for in vivo analysis of targeted agents. 10 In addition to transgenics, models that employ human tumor cells implanted in immunodeficient mice have been utilized. However, there are several drawbacks of these models as well. These limitations include the lack of precise analogy to human disease due to an immunodeficient background, as well as a disparity between transplanted versus in situ tumor biology. Furthermore, in both transgenic animals and models employing human xenografts, systemically administered targeted agents may have limited access to tumor cells due to model-specific physical barriers, such as the vascular wall or matrix components. [11] [12] [13] To circumvent such confounding variables, we sought to develop a model to allow in vivo analysis of targeted agents. Our aim was to express human tumor antigens at an anatomic site accessible to systemically delivered anticancer agents. Further, we sought to achieve overexpression of the antigen in a transient manner, which would be non-deleterious in a murine model. To this end, we explored the utility of targeted in situ gene expression via adenoviral (Ad) vector-based targeting strategies, in mice transgenic for the human coxsackie and adenovirus recptor (hCAR).
14 Our goal was to establish a 'transient transgenic' phenotype whereby the pulmonary vasculature of murine models selectively express human tumor antigens. Such a method would allow a flexible means to derive murine models for in vivo analysis of candidate targeted anti-tumor agents.
Results

Systemic administration of Ad vectors results in increased gene transfer to lungs of hCAR mice compared to wild-type mice
In the initial characterization of the transgenic hCAR mice by Tallone et al.
14 increased GFP and b-galactosidase expression was observed in the lungs of hCAR mice compared to wild-type mice. We sought to quantify precisely this difference in expression levels by comparing luciferase activity in lungs after systemic administration of AdCMVLuc. At 48 h after vector administration, we observed a notable 23-fold increase in luciferase activity in the lungs of hCAR mice compared to their littermate wild-type controls (Figure 1 ). These results show preferential gene delivery to pulmonary vasculature of hCAR mice via systemically administered Ad5-based vectors.
The endothelial-specific flt-1 promoter reduced transgene expression in the liver in hCAR mice Analysis of gene expression following AdCMVLuc administration to both wild-type and hCAR mice revealed a modest two-fold reduction of liver gene expression in hCAR mice (Figure 2 , black bars). Since hepatic Ad vector sequestration and associated gene expression presented a limit to our goal of selective transgene expression in pulmonary endothelial cells in vivo, we endeavored to accomplish a further reduction in liver gene expression by using the endothelial-specific promoter flt-1. This promoter has previously been used in our group for transcriptional targeting to endothelial cells in vivo, based upon its inductivity profile being endothelial cell 'on' and liver 'off'. This compensates for the native hepatotropism of human adenovirus after systemic administration. 15 Administration of AdfltLuc to both wild-type and hCAR mice lead to a significant reduction in liver gene expression compared to AdCMVLuc, greater than three orders of magnitude in both mouse strains ( Figure 2 , white bars). This observation thus validated the utility of transcriptional targeting to also achieve a 'liver off' transgene expression profile in the hCAR mice.
Lung-to-liver ratio is significantly increased in hCAR mice using the flt-1 promoter
To evaluate the ability of our targeting method to achieve preferential gene expression in the lungs, we calculated lung-to-liver ratios of each mouse in the experimental groups. Although the use of hCAR mice dramatically improved the lung-to-liver ratio achieved with AdCMVLuc compared to wild-type mice ( Figure 3 , black bars), the use of the endothelial-specific promoter flt-1 accomplished an additional improvement ( Figure 3 , white bars), as a result of the increased transgene expression in the lungs and the decreased transgene Inducing tumor antigens in murine lungs M Everts et al expression in the liver. This finding suggested that the employed double targeting strategy, which combined transductional and transcriptional targeting, provided an optimized target-to-liver ratio of vector-induced transgene expression.
Induction of CEA expression in pulmonary vasculature of hCAR mice Next, we sought to exploit our targeting strategy for inducing cell-specific expression of TAAs in vivo. As an initial proof-of-principle, we used the highly characterized human tumor antigen CEA. This marker can be used to study targeting strategies for CEA overexpressing cancers, such as colon cancer. In addition, we have employed this marker for immunohistochemistry to determine the cellular distribution of vector-induced gene expression in murine models of in vivo gene delivery. Analogous to the results employing luciferase as the transgene, systemic administration of AdCMVCEA resulted in increased CEA expression in the lungs of hCAR mice, with CEA being mainly expressed in capillary endothelial cells (Figure 4a (wild-type) and b (hCAR)). The administration of AdfltCEA slightly reduced overall CEA expression in both mouse strains, but was still clearly present in hCAR mice and not in wild-type mice (Figure 4c 
Discussion
Despite currently available therapies, prognosis for a variety of cancers remains poor. Considerable research efforts are being directed towards the development of new strategies for the treatment of cancer. The development of therapies targeted directly to cancer cells but not healthy tissue is especially promising due to the likelihood of reduced side effects. The development of stringent animal models is crucial for the effective evaluation and translation of candidate therapeutics into a clinical context.
We used the concept of combining transductional and transcriptional Ad targeting to achieve tissue-specific transient gene expression in vivo, as previously demonstrated in a rat model in our laboratory. 15 In this rat Figure 6 The bifunctional adapter molecule sCAR-MFE retargets AdCMVLuc to CEA-expressing lungs. hCAR mice were injected with 1 Â 10 11 vp of AdfltCEA, followed after 48 h with injection of 2 Â 10 10 vp of AdCMVLuc, preincubated with either irrelevant sCAR-C6.5 (anti-cerbB2) or sCAR-MFE (anti-CEA). Mice were killed after an additional 48 h. Results are presented as lung luciferase expression (RLU), normalized for protein content (mg protein) (a), and as lung-to-liver ratio of luciferase expression (b). Bars represent mean 7s.d., *Po0.05 (n ¼ 5 per group). Inducing tumor antigens in murine lungs M Everts et al model, transductional targeting was achieved using a Fab-9B9 conjugate, recognizing surface expressed angiotensin-converting enzyme (ACE) in the pulmonary vasculature. Endothelial-specific gene expression was achieved by transcriptional targeting using the flt-1 promoter, thus reducing gene expression in the liver.
Transition of this paradigm to a murine context was desirable for a variety of reasons, including ease of handling and reduction of expense as well as the availibility of well-characterized background and transgenic strains of mice. However, transductional targeting in mice using Fab-9B9 is not feasible because the anti-ACE 9B9 antibody does not recognize the murine ACE homologue. To circumvent this problem, we decided to utilize a transgenic hCAR mouse model. This transgenic model was developed by Tallone et al 14 and expresses a truncated, nonsignaling form of the human CAR molecule under control of the ubiquitin promoter, resulting in hCAR protein expression in all organs. In this model, systemic administration of Ad vectors resulted in increased gene expression in a subset of organs, most notably the lungs and brain, in hCAR compared to wild type mice. This was due to hCAR expression in cells previously refractory to Ad infection, such as the vascular endothelium. 14 We previously validated these findings of Tallone et al by examining the biodistribution of an Ad vector, genetically labeled with a green fluorescent protein on the capsid protein pIX, after systemic injection in wild type or hCAR mice. This experiment demonstrated an increased number of Ad particles in the lungs of transgenic mice. 16 In the present study, we further confirmed the findings of both Tallone and our laboratory by demonstrating an increased expression of luciferase in lungs of hCAR mice compared to wild-type mice, after systemic administration of AdCMVLuc. Futhermore, gene expression in livers of hCAR mice was reduced compared to wild-type mice, possibly because of increased sequestration of Ad particles in the lung vasculature after tail vein injection. Additional experiments comparing different Ad dosages and/or routes of administration will be necessary to confirm this explanation. In addition, the possibility of expression of truncated hCAR having an effect on Ad cell entry and subsequent transgene expression cannot be excluded. Regardless of the reasons underlying our observation of decreased gene expression in the liver, use of the hCAR mice can be considered as a transductional targeting method, achieving increased infection in tissues previously refractory to Ad infection.
To further limit gene expression in the liver of hCAR mice, and increase the relative selectivity of transgene expression in the pulmonary vasculature, we employed a transcriptional targeting method using the endothelial specific flt-1 promoter, similar to our previous studies. Analogous to our findings in the previously described rat model, the flt-1 promoter significantly limited transgene expression in the liver, thus futher improving lung-toliver ratio. Other (pulmonary) endothelial specific promoters might be of use to achieve either higher gene expression, or expression in a particular endothelial cell subset in the lungs. Such approaches are currently under evaluation in our laboratory.
Of relevance to systemic Ad delivery, it has recently been noted that tumor gene delivery is dependent on tumor morphology and vascularization. 11, 12 This highlights the possiblibity that the targeting potential of cancer therapeutics such as Ad vectors can be obscured by using animal models in which barriers exist that prevent the candidate agent from accessing its target molecule directly. Animal models expressing human tumor markers in an accessible site, such as the pulmonary vasculature, should be useful for evaluating basic targeting characteristics of different targeted cancer therapeutics. As a first proof of principle, we demonstrated succesful retargeting of Ad vectors to CEA in the pulmonary vasculature utilizing a bifunctional adapter molecule, comprised of the ectodomain of CAR and a single-chain antibody recognizing CEA (sCAR-MFE). Other more advanced retargeting paradigms comprise genetic engineering of capsid proteins such as fiber, 17, 18 hexon, 19 or pIX, 20 which can now be compared for their targeting capabilities in an in vivo system. Additionally, this animal model may accurately parallel situations where targeted anticancer agents recognize tumor markers expressed on neoplastic endothelium, an area that is under active investigation. [21] [22] [23] The use of Ad vectors to transiently express transgenes that induce phenotypical changes in an in vivo situation has previously been explored, including overexpression of cytokines such as interleukin-6, 24 interleukin-12, 25 or gamma interferon. 26 Additionally, nonviral methods such as cationic lipids complexed with DNA have been used to induce transient gene expression in the pulmonary vasculature of mice. 10 The animal model described herein is, to our knowledge the first report of a transient transgenic phenotype displaying TAAs in the vasculature. This new experimental model may greatly aid in the evaluation of targeting strategies for cancer.
Materials and methods
Cell culture
HEK-293 cells were obtained from Microbix (Toronto, Canada), and were maintained in DMEM:Ham's F12 (1:1 v/v) medium, containing 10% fetal bovine serum, 2 nM L-glutamine, 100 IU/ml penicillin and 25 mg/ml streptomycin. Cells were grown in a humified atmosphere with 5% CO 2 at 371C.
Virus construction and production
Ad vectors encoding either firefly luciferase (Luc) or CEA under transcriptional control of either the constitutively active cytomegalovirus (CMV) or endothelialspecific flt-1 promoter were previously constructed, as described in Reynolds et al. 15 Briefly, AdCMVLuc was constructed by amplifying the luciferase reporter gene from pGL3-Basic (Promega, Madison, WI, USA), and ligating it downstream of the CMV promoter into the Ad shuttle plasmid pShuttleCMV. 27 The recombinant Ad genome was generated by homologous recombination of the shuttle vector with pAdEasy1 in Escherichia coli strain BJ5183. Virus was rescued in 293 cells and purified using double cesium chloride (CsCl) gradient centrifugation. For this, cells were infected using medium containing 2% fetal bovine serum, and after overnight incubation regular 10% medium was added to the cells and incubated until a total cytopathic effect was observed.
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M Everts et al Cells were harvested, frozen and thawed four times, and virus was purified using standard CsCl purification methods. Viral particle number was determined by measuring absorbance at 260 nm using a conversion factor of 1.1 Â 10 12 viral particles per absorbance unit. 28 AdfltLuc was constructed in a similar manner, with the luciferase gene first being ligated into pShuttle, thus creating pShuttleLuc. Subsequently, the flt-1 promoter was amplified from pMV10-flt-1 29 and inserted upstream of the luciferase reporter gene in pShuttleLuc, thus creating pShuttlefltLuc, which was used for homologous recombination. AdfltCEA was constructed by replacing the luciferase gene in pShuttlefltLuc with human CEA, amplified from pGT37, 30 thus creating pShuttlefltCEA, which was used for subsequent homologous recombination. AdCMVCEA was constructed as described in Raben et al. 31 Construction, production, and purification of retargeting adapter molecules sCAR-MFE and sCAR-C6.5
A fusion protein capable of retargeting Ad vectors to the TAA CEA was constructed, consisting of the ectodomain of CAR including its own leader sequence (aa 1-236), followed by a 5-aa peptide linker (GGPGS), a 6-histidine tag (for detection/purification), followed by the anti-CEA single-chain antibody MFE-23 (a kind gift from Dr Kerry Chester, London, UK). A similar fusion protein was constructed containing the anti-c-erbB2 single-chain antibody C6.5 (provided by Dr JD Marks, University of California San Francisco, CA, USA) in place of MFE-23. To construct sCAR-MFE and sCAR-C6.5, first, cDNA encoding sCAR followed by the 6-his tag was amplified out of pFBsCAR6hTf, 32 introducing a HindIII (5 0 ) and maintaining the BamHI (3 0 ) restriction site. Second, the scFv cDNAs encoding either MFE-23 or C6.5 were amplified by PCR introducing a BamHI (5 0 ) and XhoI (3 0 ) restriction site. Both sCAR and scFv PCR products were simultaneously ligated into the pcDNA3.1 plasmid (Invitrogen, Carlsbad, CA, USA), digested with HindIII and XhoI restriction enzymes, thereby creating pcDNA/ sCAR/6h/MFE or pcDNA/sCAR/6h/C6.5. The constructed plasmids were verified by sequencing. HEK-293 cells were stably transfected with PvuI linearized plasmids, and clones were selected for high production and secretion of protein in the supernatant. After expansion of a positive clone, medium was collected and protein was purified by immobilized metal-affinity chromatography (Ni-NTA Superflow, Qiagen, Valencia, CA, USA), followed by dialysis with PBS.
Animals
Transgenic hCAR mice were a generous gift from Dr S Petterson, Karolinska Institute, Sweden. These mice express a human CAR (hCAR) gene lacking the cytoplasmic tail, under control of the human ubiquitin-C promoter, thus allowing hCAR to be expressed in a variety of tissues, including the liver, kidney, heart, lungs, brain, and muscle. 14 In this study, 9-12-week-old mice were used, either with the hCAR phenotype or littermate negative controls (wild-type). Mice were screened for the presence of hCAR in their genome using PCR and flow cytometry. Mice were kept under pathogen-free conditions according to the American Association for Accreditation of Laboratory Animal Care guidelines, with access to standard chow and water ad libitum. Animal experiments and protocols were reviewed and approved by the Institutional Animal Care and Use Committee of University of Alabama at Birmingham.
In vivo gene transfer Luciferase gene delivery. AdCMVLuc or AdfltLuc viral preparations were diluted with sterile PBS to a concentration of 1.5 Â 10 11 vp/200 ml. Mice (n ¼ 5 per group) were injected via the tail vein, and killed after 48 h by CO 2 inhalation. Organs were excised and stored at À801C until further analysis. Frozen organs were ground to a fine powder using a morter and pestel, cooled in a dry ice-ethanol bath. Organ powders were lysed using Cell Culture Lysis Buffer (Promega) at room temperature for 20 min. Lysates were frozen and thawed once, and centrifuged at 14 000 r.p.m. for 15 min in a tabletop Eppendorf centrifuge. Luciferase activity in 1:20 diluted samples was measured using the Luciferase Assay System (Promega), according to the manufacturer's instructions. Luciferase values were normalized for protein content, as determined using the Bio-Rad DC Protein Assay system (Bio-Rad, Hercules, CA, USA).
CEA gene delivery and immunohistochemistry. AdCMV-CEA or AdfltCEA viral preparations were diluted and injected as described above (n ¼ 3). After 48 h, mice were killed and whole body perfusion was performed using heparinized PBS followed by neutral-buffered formalin. Lungs were inflated with formalin as previously described. 33 Organs were fixed overnight in formalin, embedded into paraffin, sectioned, and stained using a rabbit anti-CEA antibody (Chemicon), followed by an HRP-conjugated goat anti-rabbit secondary antibody (DakoCytomation, Carpinteria, CA, USA). Color was developed using di-aminobenzidine (DAB, Pierce, Rockford, IL, USA).
Targeting AdCMVLuc to CEA using bifunctional adapter molecules. hCAR mice were injected with AdfltCEA as described above (n ¼ 5), thus inducing CEA expression in the pulmonary vasculature. After 2 days, 2 Â 10 10 vp/mouse AdCMVLuc was preincubated with 300 ng of either sCAR-MFE or sCAR-C6.5 for 30 min at room temperature and subsequently administered to CEA-expressing hCAR mice via tail vein injection. After 48 h, mice were killed, organs were excised and analyzed for luciferase expression as described above.
Statistics
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